<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作為您在 Google 上的首選新聞來源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>Assertio Holdings, Inc. (ASRT) 週三宣佈，Zydus Worldwide DMCC（Zydus Lifesciences Ltd. 的子公司）同意以約 1.664 億美元現金收購 Assertio，或每股 23.50 美元。</p>
<p>該交易預計將在 2026 年第二季度完成。</p>
<p>該報價相較於 4 月 8 日與 GUARD.ST 宣佈的每股 18 美元的全現金交易溢價 30.6%。</p>
<p>該報價還相較於 5 月 4 日宣佈的修訂後每股 21.80 美元的 Garda 交易溢價 7.8%。</p>
<p>該交易進一步相較於 Assertio 在 3 月 20 日的未受影響收盤股價溢價 75.8%。</p>
<p>公司還表示，董事會確定 Zydus 的報價構成修訂後的 Garda 合併協議下的 “優越提案”，並授權終止 Garda 協議以進入 Zydus 交易。</p>
<p>根據協議，Zydus 將開始以每股 23.50 美元現金收購所有未流通的 Assertio 普通股的要約。</p>
<p>交易完成後，Assertio 的普通股將不再在納斯達克上市。</p>
<p>Zydus Lifesciences 在國家證券交易所的交易收盤上漲 0.92%，報 939.25 印度盧比。</p>
<p>在盤前交易中，Assertio 上漲 3.68%，報 23.38 美元，納斯達克。</p>
<p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
<p>商業新聞</p>

ASRT

<p>Assertio Holdings, Inc. (ASRT) 宣佈，Zydus Worldwide DMCC（Zydus Lifesciences Ltd. 的子公司）將以約 1.664 億美元現金收購 Assertio，摺合每股 23.50 美元。該交易預計將在 2026 年第二季度完成，較 Garda 之前的報價溢價 30.6%。Assertio 的董事會認為 Zydus 的報價是 “優越提案”，因此終止了與 Garda 的協議。收購完成後，Assertio 的股票將從納斯達克退市</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作為您在 Google 上的首選新聞來源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Assertio Holdings, Inc. (ASRT), on Wednesday, announced that Zydus Worldwide DMCC, a subsidiary of Zydus Lifesciences Ltd. (ZYDUSLIFE.BO,ZYDUSLIFE.NS), agreed to acquire Assertio for approximately $166.4 million in cash, or $23.50 per share.</p>
<div class="lb-trans"><p>Assertio Holdings, Inc. (ASRT) 週三宣佈，Zydus Worldwide DMCC（Zydus Lifesciences Ltd. 的子公司）同意以約 1.664 億美元現金收購 Assertio，或每股 23.50 美元。</p>
</div><p>The transaction is expected to close in the second quarter of 2026.</p>
<div class="lb-trans"><p>該交易預計將在 2026 年第二季度完成。</p>
</div><p>The offer represents a 30.6% premium to the $18 per share all-cash transaction with GUARD.ST announced on April 8.</p>
<div class="lb-trans"><p>該報價相較於 4 月 8 日與 GUARD.ST 宣佈的每股 18 美元的全現金交易溢價 30.6%。</p>
</div><p>The offer also represents a 7.8% premium to the revised $21.80 per share Garda transaction announced on May 4.</p>
<div class="lb-trans"><p>該報價還相較於 5 月 4 日宣佈的修訂後每股 21.80 美元的 Garda 交易溢價 7.8%。</p>
</div><p>The transaction further represents a 75.8% premium to Assertio's unaffected closing stock price on March 20.</p>
<div class="lb-trans"><p>該交易進一步相較於 Assertio 在 3 月 20 日的未受影響收盤股價溢價 75.8%。</p>
</div><p>The company also said that the board determined that the Zydus offer constituted a &#34;Superior Proposal&#34; under the revised Garda merger agreement and authorized the termination of the Garda agreement to enter into the Zydus transaction.</p>
<div class="lb-trans"><p>公司還表示，董事會確定 Zydus 的報價構成修訂後的 Garda 合併協議下的 “優越提案”，並授權終止 Garda 協議以進入 Zydus 交易。</p>
</div><p>Under the agreement, Zydus will commence a tender offer to acquire all outstanding shares of Assertio common stock for $23.50 per share in cash.</p>
<div class="lb-trans"><p>根據協議，Zydus 將開始以每股 23.50 美元現金收購所有未流通的 Assertio 普通股的要約。</p>
</div><p>Following completion of the transaction, Assertio's common stock will no longer be listed on Nasdaq.</p>
<div class="lb-trans"><p>交易完成後，Assertio 的普通股將不再在納斯達克上市。</p>
</div><p>Zydus Lifesciences closed trading 0.92% higher at INR 939.25 on the National Stock Exchange.</p>
<div class="lb-trans"><p>Zydus Lifesciences 在國家證券交易所的交易收盤上漲 0.92%，報 939.25 印度盧比。</p>
</div><p>In the pre-market trading, Assertio is 3.68% higher at $23.38 on the Nasdaq.</p>
<div class="lb-trans"><p>在盤前交易中，Assertio 上漲 3.68%，報 23.38 美元，納斯達克。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商業新聞</p>
</div>

Assertio 終止了與 Garda 的協議，並同意以 1.664 億美元被 Zydus Worldwide DMCC 收購